Biotech Short Interest Sinks
The December 15 short interest data have been compared with the previous report, and short interest was down in most of the selected biotech stocks.
The December 15 short interest data have been compared with the previous report, and short interest was down in most of the selected biotech stocks.
Tthe top analyst upgrades, downgrades and initiations seen on Tuesday morning include Amgen, American Express, American Water Works, Celgene and Square.
The top analyst upgrades, downgrades and initiations seen on Tuesday morning include Amgen, Coca-Cola, IBM, Procter & Gamble, Viacom, SeaWorld and NovoCure.
The November 30 short interest data have been compared with the previous report, and short interest was mixed in the selected biotech stocks.
The November 15 short interest data have been compared with the previous report, and short interest increased in most of the selected biotech stocks.
With the Republicans now set to control both Congress and the White House, many on Wall Street feel that there could be far less scrutiny on drug pricing.
Now that the U.S. presidential election is over and Hillary Clinton is out of the picture, major biotech companies can breathe a little easier knowing that the pressure is off, if for…
The broad markets are holding steady near their double bottom set this summer. However, over the course of the past week this has been tested.
Though Amgen reported better-than-expected third-quarter results on Thursday, shares sank early Friday.
Biotech giant Amgen is scheduled to release its third-quarter financial results after the markets close on Thursday.
The October 14 short interest data have been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
Earnings season is now in full swing, and we have put together a preview of Bristol-Myers, AbbVie and some of the other top players in the health care sector.
Americans generally would like to spend less money on health care. One way that this can be and will be accomplished is through the continued use and expanded use of generic drugs.
These top biotech companies have been absolutely hammered and now trade at a valuation much lower than large cap pharmaceuticals.
If a single failed clinical trial can mean disaster for a biotech stock, then short sellers can argue for a stock implosion down the road.